The US Food and Drug Administration’s Center for Biologics Evaluation and Research has suspended the biologics license for Ixchiq, a live-attenuated chikungunya vaccine developed by Valneva. The move comes after reports of “serious safety concerns” related to the vaccine, which have caused chikungunya-like illness in some individuals who received it. This suspension marks a significant setback for the vaccine, which was cleared under accelerated approval less than two years ago.
Source: https://www.statnews.com/2025/08/25/biotech-news-fda-paxil-gsk-chikungunya-vaccine